Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
Insulin-sensitizing peptides warrant caution given Retatrutides glucose effects
Well, rather than supplementing with folic acid, which would likely accumulate due to a lack of MTHFR to process it, consider an active folate supplement instead that contains methylfolate
Medical Tests: Your doctor may order frequent medical tests to monitor your blood count, potassium levels, and vitamin B12 levels, assessing the effectiveness of the treatment
Oleocanthal inhibits catabolic and inflammatory mediators in LPS-activated human primary osteoarthritis (OA) chondrocytes through MAPKs/NF-B pathways
